HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Combination Trial

By HEOR Staff Writer

November 14, 2025

Breakthrough Single-Tablet Regimen Drives HIV Therapy Advancements Gilead Sciences has announced promising topline results from the Phase 3 ARTISTRY-1 trial, demonstrating that an investigational single-tablet regim...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost Treatments

By João L. Carapinha

Evolving Landscape of Targeted Therapies and Access Challenges Expanding targeted therapy access remains a critical challenge amid the pharmaceutical market's shift toward high-cost innovations, such as orphan drugs and...
Weight Loss: Advances in Hormone-Based Obesity Treatments

By HEOR Staff Writer

November 12, 2025

Advances in Hormone-Based Pharmacotherapies for Obesity Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges

By HEOR Staff Writer

NICE's Unified Prioritization Roadmap NICE NHS prioritization has led to a new, unified framework and board that will tackle emerging healthcare innovations while managing finite assessment capacity. The approach focuses on high-impact areas, including mental health, early cancer detect...
Beta-Blockers in Heart Attack Recovery: Reevaluating Their Role Based on Recent Research Insights

By HEOR Staff Writer

November 10, 2025

Beta-Blockers Heart Attack Research: Key Findings from Recent Meta-Analysis Have you wondered if beta-blockers truly benefit heart attack survivors with normal heart function? Beta-blockers heart attack rese...
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions

By HEOR Staff Writer

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...
View All News
Search By Category

Syenza's Top Picks

Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025

Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

FDA Guidance on Overall Survival Assessment in Oncology Trials

Empowering Innovation: Clinical Trials Reform Strategies by EMA for 2025

Mounjaro Price Increase UK: Impacts on Access and Health Economics

Biosimilars Market Trends 2025: Understanding Erosion and Growth

Latest

HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Combination Trial

By HEOR Staff Writer

November 14, 2025

Breakthrough Single-Tablet Regimen Drives HIV Therapy Advancements Gilead Sciences has announced promising topline results from the Phase 3 ARTISTRY-1 trial, demonstrating that an investigational single-tablet regim...

Latest

Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost Treatments

By João L. Carapinha

Evolving Landscape of Targeted Therapies and Access Challenges Expanding targeted therapy access remains a critical challenge amid the pharmaceutical market's shift toward high-cost innovations, such as orphan drugs and...

Latest

Weight Loss: Advances in Hormone-Based Obesity Treatments

By HEOR Staff Writer

November 12, 2025

Advances in Hormone-Based Pharmacotherapies for Obesity Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent

Latest

NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges

By HEOR Staff Writer

NICE's Unified Prioritization Roadmap NICE NHS prioritization has led to a new, unified framework and board that will tackle emerging healthcare innovations while managing finite assessment capacity. The approach focuses on high-impact areas, including mental health, early cancer detect...

Global Updates

Weight Loss: Advances in Hormone-Based Obesity Treatments

By HEOR Staff Writer

Advances in Hormone-Based Pharmacotherapies for Obesity Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent

Global Updates

CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...

Global Updates

Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential

By HEOR Staff Writer

November 7, 2025

Are you wondering about the latest eloralintide obesity treatment options? Eloralintide, a selective amylin receptor agonist, has shown promising results in managing obesity. In a recent phase 2 trial, it led to significant weight loss of up to 20% over 48 weeks in adults with obesity or overweig...

Global Updates

Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks

By HEOR Staff Writer

November 3, 2025

Antidepressant side effects vary widely among medications, impacting heart health, weight, and metabolism in distinct ways. If you're wondering how these drugs affect your body, a recent systematic review and network meta-analysis in The Lancet shows key differences. For ex...

Europe

View All
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges

By HEOR Staff Writer

November 12, 2025

NICE's Unified Prioritization Roadmap NICE NHS prioritization has led to a new, unified framework and board that will tackle emerging healthcare innovations while managing finite assessment capacity. The approach focuses on high-impact areas, including mental health, early cancer detect...
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients

By HEOR Staff Writer

November 7, 2025

European Commission Approves Koselugo for Adult NF1 Patients The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Efficiency

By HEOR Staff Writer

November 5, 2025

UK Clinical Trial Reforms Slash Approval Times UK Clinical Trial Reforms have accelerated clinical trial approvals, reducing average times from 91 days to 41 days through risk-proportionate changes at the Medicines and Healthcare produ...

North America

View All
HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Combination Trial

By HEOR Staff Writer

November 14, 2025

Breakthrough Single-Tablet Regimen Drives HIV Therapy Advancements Gilead Sciences has announced promising topline results from the Phase 3 ARTISTRY-1 trial, demonstrating that an investigational single-tablet regim...
Weight Loss: Advances in Hormone-Based Obesity Treatments

By HEOR Staff Writer

November 12, 2025

Advances in Hormone-Based Pharmacotherapies for Obesity Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent
Beta-Blockers in Heart Attack Recovery: Reevaluating Their Role Based on Recent Research Insights

By HEOR Staff Writer

November 10, 2025

Beta-Blockers Heart Attack Research: Key Findings from Recent Meta-Analysis Have you wondered if beta-blockers truly benefit heart attack survivors with normal heart function? Beta-blockers heart attack rese...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential

By HEOR Staff Writer

November 7, 2025

Are you wondering about the latest eloralintide obesity treatment options? Eloralintide, a selective amylin receptor agonist, has shown promising results in managing obesity. In a recent phase 2 trial, it led to significant weight loss of up to 20% over 48 weeks in adults with obesity or overweig...

Sub-Saharan Africa

View All
AI in South African Healthcare: Professionals’ Confidence in Reducing Admissions and Enhanc...

By HEOR Staff Writer

November 5, 2025

AI Optimism in South Africa's Healthcare Landscape AI in South African Healthcare is gaining momentum, as evidenced by the Philips Future Health Index (FHI...
Shifting Toward Sustainable Reimbursement Models in South Africa’s Healthcare Sector

By João L. Carapinha

November 4, 2025

Escaping Fee-for-Service: Pathways to Sustainable Reimbursement Models The Council for Medical Schemes (CMS) Annual Report 2024/25 undersc...
Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 2024/25

By João L. Carapinha

October 31, 2025

The CMS Annual Report 2024/25 highlights significant medical schemes affordability challenges in South Africa, where relevant healthcare expenditure per beneficiary surged by 8.70% year-on-year, far outpacing both contribution growth and general inflation. Solvency ratios have declined for three ...
Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurement Challenges

By João L. Carapinha

October 30, 2025

African Pharmaceutical Growth African Pharmaceutical Growth remains stifled by significant barriers, as highlighted in a recent plenary address at the Conference on Public Health in Africa (CPHIA) 2025 (reported by Health Policy Watch). Dr. Stavros Nicolaou, group senior executive for s...